InfuSystem Reports First Quarter 2022 Financial Results
InfuSystem Holdings, Inc. (NYSE: INFU) announced a 9% revenue increase for Q1 2022, totaling $26.8 million. Growth was driven by a 5% rise in Integrated Therapy Services and an 18% rise in Durable Medical Equipment Services. Although gross profit rose to $15.4 million, the gross margin decreased to 57.4%. InfuSystem signed a three-year Master Service Agreement with a leading medical technology company, potentially generating $10-12 million in annual revenue. Operating cash flow surged 54% to $4.1 million, but a net loss of $0.4 million was reported. The company expects 15-20% revenue growth for the full year.
- Signed a 3-year Master Service Agreement, potentially generating $10-12 million in annual revenue.
- Revenue growth of 9% in Q1 2022, totaling $26.8 million.
- Strong operating cash flow growth of 54% to $4.1 million.
- Durable Medical Equipment Services revenue rose by 18%.
- Expecting full-year revenue growth guidance of 15-20%.
- Net loss of $0.4 million for Q1 2022.
- Adjusted EBITDA decreased by 33% to $4.1 million.
- Gross margin fell to 57.4%, down from 59.6%.
Signed 3-year Master Service Agreement with
Revenue Growth of
Strong Operating Cash Flow Growth of
Repurchased Approximately
2022 First Quarter Overview:
-
Net revenues totaled
, an increase of$26.8 million 9% vs. prior year.-
Integrated Therapy Services ("ITS") net revenue was
, an increase of$16.6 million 5% vs. prior year. -
Durable Medical Equipment Services ("DME Services") net revenue was
, an increase of$10.1 million 18% vs. prior year.
-
Integrated Therapy Services ("ITS") net revenue was
-
Gross profit was
, an increase of$15.4 million 5% vs. prior year. -
Gross margin was
57.4% , a decrease of2.2% vs. prior year partly impacted by investments made to train additional technical staff to prepare for anticipated growth in biomedical services. -
Net loss of
, or$0.4 million per diluted share.$(0.02) -
Adjusted earnings before interest, income taxes, depreciation, and amortization (“Adjusted EBITDA”) (non-GAAP) was
, a decrease of$4.1 million 33% vs. prior year primarily impacted by investments in the sales force to capture additional market share in Pain Management and Negative Pressure Wound Therapy ("NPWT") and the increased biomedical services training costs. -
Net cash provided by operations was
, an increase of$4.1 million 54% vs. prior year.
Management Discussion
Chief Executive Officer of
“We are building momentum for another record year in 2022, as we announced a significant milestone last week in a press release with the signing of a three-year master service agreement with a leading global healthcare technology and diagnostic company. We expect to provide biomedical services, which includes preventative maintenance and repair solutions, for the majority of their more than 300,000 pumps located in 1,200 medical facilities, including 800 hospital systems in the
“We made the strategic decision in 2021 to invest in building our Pain and Wound Care sales teams along with hiring and training biomedical service technicians. As a result of our growth investments, operating expenses for the first quarter increased
“Looking forward, we are estimating full-year 2022 revenue growth to be in the range of
2022 First Quarter Financial Review
Net revenues for the quarter ended
ITS net revenue of
DME Services net revenue of
Gross profit for the first quarter of 2022 of
ITS gross profit was
DME Services gross profit during the first quarter of 2022 was
Selling and marketing expenses for the first quarter of 2022 were
G&A expenses for the first quarter of 2022 were
Net loss for the first quarter of 2022 was
Adjusted EBITDA, a non-GAAP measure, for the first quarter of 2022 was
Balance sheet, cash flows and liquidity
During the three-month period ended
Available liquidity totaled
Full Year 2022 Guidance
The full year 2022 guidance reflects management’s current expectation for operational performance, given the current market conditions. The Company and its businesses are subject to certain risks, including those risk factors discussed in our most recent annual report on Form 10-K for the year ended
Conference Call
The Company will conduct a conference call for all interested investors on
To participate in this call, please dial (888) 567-1603 or (862) 298-0702, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (888) 539-4649 or (754) 333-7735, confirmation code 157114, through
Non-GAAP Measures
This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. Non-GAAP financial measures presented in this press release include EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and net debt. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company’s management, investors and other interested parties about the Company’s operating performance because they allow them to understand and compare the Company’s operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring or non-core items that are not part of the normal course of business. A reconciliation of those measures to the most directly comparable GAAP measures is provided in the accompanying schedule, titled "GAAP to Non-GAAP Reconciliation" below. Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, items included in the accompanying schedule below. Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as nonrecurring, unusual or unanticipated changes, expenses or gains or other items that may not directly correlate to the underlying performance of our business operations. The exact amounts of these adjustments are not currently determinable but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP guidance to the most comparable GAAP measures.
About
Forward-Looking Statements
The financial results in this press release reflect preliminary results, which are not final until the Company’s quarterly report on Form 10-Q for the quarter ended
Additional information about
FINANCIAL TABLES FOLLOW
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
|||||||
|
Three Months Ended
|
||||||
(in thousands, except share and per share data) |
|
2022 |
|
|
|
2021 |
|
|
|
|
|
||||
Net revenues |
$ |
26,763 |
|
|
$ |
24,463 |
|
Cost of revenues |
|
11,396 |
|
|
|
9,887 |
|
Gross profit |
|
15,367 |
|
|
|
14,576 |
|
|
|
|
|
||||
Selling, general and administrative expenses: |
|
|
|
||||
Provision for doubtful accounts |
|
47 |
|
|
|
(70 |
) |
Amortization of intangibles |
|
710 |
|
|
|
1,043 |
|
Selling and marketing |
|
3,319 |
|
|
|
2,376 |
|
General and administrative |
|
11,816 |
|
|
|
10,354 |
|
|
|
|
|
||||
Total selling, general and administrative |
|
15,892 |
|
|
|
13,703 |
|
|
|
|
|
||||
Operating (loss) income |
|
(525 |
) |
|
|
873 |
|
Other expense: |
|
|
|
||||
Interest expense |
|
(277 |
) |
|
|
(322 |
) |
Other expense |
|
(28 |
) |
|
|
(69 |
) |
|
|
|
|
||||
(Loss) income before income taxes |
|
(830 |
) |
|
|
482 |
|
Benefit from income taxes |
|
462 |
|
|
|
179 |
|
Net (loss) income |
$ |
(368 |
) |
|
$ |
661 |
|
Net (loss) income per share |
|
|
|
||||
Basic |
$ |
(0.02 |
) |
|
$ |
0.03 |
|
Diluted |
$ |
(0.02 |
) |
|
$ |
0.03 |
|
Weighted average shares outstanding: |
|
|
|
||||
Basic |
|
20,609,372 |
|
|
|
20,338,160 |
|
Diluted |
|
20,609,372 |
|
|
|
21,937,639 |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS SEGMENT REPORTING (UNAUDITED) |
||||||||||||
|
|
Three Months Ended
|
|
Better/ (Worse) |
||||||||
(in thousands) |
|
|
2022 |
|
|
|
2021 |
|
|
|||
|
|
|
|
|
|
|
||||||
Net revenues: |
|
|
|
|
|
|
||||||
ITS |
|
$ |
16,641 |
|
|
$ |
15,911 |
|
|
$ |
730 |
|
DME Services (inclusive of inter-segment revenues) |
|
|
11,610 |
|
|
|
9,998 |
|
|
|
1,612 |
|
Less: elimination of inter-segment revenues |
|
|
(1,488 |
) |
|
|
(1,446 |
) |
|
|
(42 |
) |
Total |
|
|
26,763 |
|
|
|
24,463 |
|
|
|
2,300 |
|
Gross profit (inclusive of certain inter-segment allocations) (a): |
|
|
|
|
|
|
||||||
ITS |
|
|
10,738 |
|
|
|
10,003 |
|
|
|
735 |
|
DME Services |
|
|
4,629 |
|
|
|
4,573 |
|
|
|
56 |
|
Total |
|
$ |
15,367 |
|
|
$ |
14,576 |
|
|
$ |
791 |
|
(a) Inter-segment allocations are for cleaning and repair services performed on medical equipment. |
GAAP TO NON-GAAP RECONCILIATION (UNAUDITED)
|
||||||||
NET (LOSS) INCOME TO EBITDA, ADJUSTED EBITDA, NET (LOSS) INCOME MARGIN AND ADJUSTED EBITDA MARGIN: |
||||||||
|
|
Three Months Ended
|
||||||
(in thousands) |
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
|
||||
GAAP net (loss) income |
|
$ |
(368 |
) |
|
$ |
661 |
|
Adjustments: |
|
|
|
|
||||
Interest expense |
|
|
277 |
|
|
|
322 |
|
Income tax benefit |
|
|
(462 |
) |
|
|
(179 |
) |
Depreciation |
|
|
2,706 |
|
|
|
2,527 |
|
Amortization |
|
|
710 |
|
|
|
1,043 |
|
|
|
|
|
|
||||
Non-GAAP EBITDA |
|
$ |
2,863 |
|
|
$ |
4,374 |
|
|
|
|
|
|
||||
Stock compensation costs |
|
|
1,047 |
|
|
|
1,635 |
|
Medical equipment reserve (1) |
|
|
170 |
|
|
|
468 |
|
Acquisition costs |
|
|
— |
|
|
|
38 |
|
SOX readiness costs |
|
|
40 |
|
|
|
— |
|
Management reorganization/transition costs |
|
|
14 |
|
|
|
3 |
|
Certain other non-recurring costs |
|
|
8 |
|
|
|
(358 |
) |
|
|
|
|
|
||||
Non-GAAP Adjusted EBITDA |
|
$ |
4,142 |
|
|
$ |
6,160 |
|
|
|
|
|
|
||||
GAAP Net Revenues |
|
$ |
26,763 |
|
|
$ |
24,463 |
|
Net (Loss) Income Margin (2) |
|
|
(1.4 |
) % |
|
|
2.7 |
% |
Non-GAAP Adjusted EBITDA Margin (3) |
|
|
15.5 |
% |
|
|
25.2 |
% |
(1) |
Amounts represent a non-cash expense recorded to adjust reserve for missing medical equipment and is being added back due to its similarity to depreciation. |
(2) |
Net (Loss) Income Margin is defined as GAAP Net (Loss) Income as a percentage of GAAP Net Revenues. |
(3) |
Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues. |
CONSOLIDATED BALANCE SHEETS (UNAUDITED) |
||||||||
|
|
As of |
||||||
(in thousands, except par value and share data) |
|
|
|
|
||||
|
|
|
|
|
||||
ASSETS |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
405 |
|
|
$ |
186 |
|
Accounts receivable, net |
|
|
16,392 |
|
|
|
15,405 |
|
Inventories |
|
|
3,878 |
|
|
|
3,939 |
|
Other current assets |
|
|
2,585 |
|
|
|
2,535 |
|
|
|
|
|
|
||||
Total current assets |
|
|
23,260 |
|
|
|
22,065 |
|
Medical equipment for sale or rental |
|
|
1,987 |
|
|
|
1,742 |
|
Medical equipment in rental service, net of accumulated depreciation |
|
|
39,113 |
|
|
|
39,871 |
|
Property & equipment, net of accumulated depreciation |
|
|
4,375 |
|
|
|
4,523 |
|
|
|
|
3,710 |
|
|
|
3,710 |
|
Intangible assets, net |
|
|
10,219 |
|
|
|
10,930 |
|
Operating lease right of use assets |
|
|
3,916 |
|
|
|
4,241 |
|
Deferred income taxes |
|
|
10,277 |
|
|
|
10,033 |
|
Other assets |
|
|
1,380 |
|
|
|
471 |
|
|
|
|
|
|
||||
Total assets |
|
$ |
98,237 |
|
|
$ |
97,586 |
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
8,242 |
|
|
$ |
7,862 |
|
Current portion of long-term debt |
|
|
156 |
|
|
|
349 |
|
Other current liabilities |
|
|
5,543 |
|
|
|
4,685 |
|
|
|
|
|
|
||||
Total current liabilities |
|
|
13,941 |
|
|
|
12,896 |
|
Long-term debt, net of current portion |
|
|
34,792 |
|
|
|
32,748 |
|
Operating lease liabilities, net of current portion |
|
|
3,451 |
|
|
|
3,670 |
|
|
|
|
|
|
||||
Total liabilities |
|
|
52,184 |
|
|
|
49,314 |
|
|
|
|
|
|
||||
Stockholders’ equity: |
|
|
|
|
||||
Preferred stock, |
|
|
— |
|
|
|
— |
|
Common stock, |
|
|
2 |
|
|
|
2 |
|
Additional paid-in capital |
|
|
103,373 |
|
|
|
101,905 |
|
Accumulated other comprehensive income |
|
|
955 |
|
|
|
268 |
|
Retained deficit |
|
|
(58,277 |
) |
|
|
(53,903 |
) |
|
|
|
|
|
||||
Total stockholders’ equity |
|
|
46,053 |
|
|
|
48,272 |
|
|
|
|
|
|
||||
Total liabilities and stockholders’ equity |
|
$ |
98,237 |
|
|
$ |
97,586 |
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||||||
|
|
Three Months Ended |
||||||
(in thousands) |
|
|
2022 |
|
|
|
2021 |
|
|
|
|
|
|
||||
OPERATING ACTIVITIES |
|
|
|
|
||||
Net (loss) income |
|
$ |
(368 |
) |
|
$ |
661 |
|
Adjustments to reconcile net (loss) income to net cash provided by operating activities: |
|
|
|
|
||||
Provision for doubtful accounts |
|
|
47 |
|
|
|
(70 |
) |
Depreciation |
|
|
2,706 |
|
|
|
2,527 |
|
Loss on disposal of and reserve adjustments for medical equipment |
|
|
275 |
|
|
|
597 |
|
(Gain) loss on sale of medical equipment |
|
|
(228 |
) |
|
|
89 |
|
Amortization of intangible assets |
|
|
710 |
|
|
|
1,043 |
|
Amortization of deferred debt issuance costs |
|
|
18 |
|
|
|
96 |
|
Stock-based compensation |
|
|
1,047 |
|
|
|
1,635 |
|
Deferred income taxes |
|
|
(462 |
) |
|
|
(180 |
) |
Changes in assets - (increase)/decrease: |
|
|
|
|
||||
Accounts receivable |
|
|
(1,278 |
) |
|
|
(420 |
) |
Inventories |
|
|
61 |
|
|
|
(154 |
) |
Other current assets |
|
|
(50 |
) |
|
|
(244 |
) |
Other assets |
|
|
(41 |
) |
|
|
(40 |
) |
Changes in liabilities - increase/(decrease): |
|
|
|
|
||||
Accounts payable and other liabilities |
|
|
1,641 |
|
|
|
(2,889 |
) |
NET CASH PROVIDED BY OPERATING ACTIVITIES |
|
|
4,078 |
|
|
|
2,651 |
|
|
|
|
|
|
||||
INVESTING ACTIVITIES |
|
|
|
|
||||
Acquisition of business |
|
|
— |
|
|
|
(1,204 |
) |
Purchase of medical equipment |
|
|
(2,931 |
) |
|
|
(2,336 |
) |
Purchase of property and equipment |
|
|
(178 |
) |
|
|
(138 |
) |
Proceeds from sale of medical equipment, property and equipment |
|
|
966 |
|
|
|
876 |
|
|
|
|
(2,143 |
) |
|
|
(2,802 |
) |
|
|
|
|
|
||||
FINANCING ACTIVITIES |
|
|
|
|
||||
Principal payments on long-term debt |
|
|
(10,696 |
) |
|
|
(40,093 |
) |
Cash proceeds from long-term debt |
|
|
12,529 |
|
|
|
34,000 |
|
Debt issuance costs |
|
|
— |
|
|
|
(386 |
) |
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans |
|
|
(54 |
) |
|
|
(565 |
) |
Common stock repurchased as part of share repurchase program |
|
|
(4,006 |
) |
|
|
— |
|
Cash proceeds from stock plans |
|
|
511 |
|
|
|
308 |
|
|
|
|
(1,716 |
) |
|
|
(6,736 |
) |
|
|
|
|
|
||||
Net change in cash and cash equivalents |
|
|
219 |
|
|
|
(6,887 |
) |
Cash and cash equivalents, beginning of period |
|
|
186 |
|
|
|
9,648 |
|
Cash and cash equivalents, end of period |
|
$ |
405 |
|
|
$ |
2,761 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005384/en/
602-889-9700
Source:
FAQ
What were InfuSystem's Q1 2022 revenue figures?
What is the expected revenue growth for InfuSystem in 2022?
Did InfuSystem repurchase any of its stocks in Q1 2022?
What was InfuSystem's net loss in Q1 2022?